Is Nuvilex Ready to Acquire Diabetes Technology and Control Cancer and Diabetes Cell Encapsulation Markets?

NEW YORK, NY--(Marketwired - Nov 1, 2013) - With October behind us, Nuvilex, Inc. (OTCQB: NVLX) investors should see a new acquisition this month. Two weeks ago Stock Market Media Group, a research and content development investor relations firm, released an audio interview with Nuvilex's COO, Dr. Gerald Crabtree, where he discussed many topics including; the company's future Phase III clinical trials, study sites, the goals of the trials, and why he feels the company's unique live-cell encapsulation-based platform technology is better than any other cell encapsulation out there. Listen to the interview: www.stockmarketmediagroup.com/media. 

In July, Nuvilex acquired the exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment it will be using in the company's future Phase III clinical trials. These licenses include worldwide rights to utilize the live-cell encapsulation platform technology to develop treatments for any and all cancer types, regardless of the cell type encapsulated.

Soon after the acquisition for the cancer technology, Nuvilex's management announced that it anticipated it would close the acquisition for the exclusive rights to a live-cell encapsulation-based therapy to treat diabetes in October. When Nuvilex pulls off this acquisition, it will control 2 of the big 3 multi-billion dollar drug markets -- cancer and diabetes -- with regard to the use of this unique and proprietary live-cell encapsulation-based technology.

According to the American Diabetes Association, in the U.S. alone, $176 billion is spent annually on medical costs associated with diabetes with over $22 billion of that being spent on treatments for the disease. Recent estimates project that as many as one in three American adults will have diabetes by 2050. With these numbers growing dramatically, so too are the costs for treatment.

So, November should hold good news for investors with Nuvilex set to control any future therapies for diabetes and any form of cancer that uses the live-cell encapsulation-based technology, and for technical traders, now that the stock has filled the gap below $0.113, the announcement could be perfectly timed.

About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles. For more information and to read disclaimers and disclosures: www.stockmarketmediagroup.com